Harvey Risch, professor of epidemiology at Yale School of Public Health, says that hydroxychloroquine is "The key to defeating COVID-19" in a Newsweek op-ed published this past week.
The New York Times even alleged that Trump's motivation for touting the drug was self-serving because he holds "a small personal financial interest" in Sanofi, even though the drug is out of patent and he only owned $29 - $435 in stock as part of a mutual fund.
The VA study wasn't a clinical trial, but a small, non-peer-reviewed study of patients who were not representative of the entire population, and those with more severe COVID-19 cases were disproportionally administered the drug.
The media ignored a survey of doctors back in May that found an overwhelming majority of them "Would prescribe hydroxychloroquine or another anti-malaria drug to a family member" suffering from the coronavirus.
CNN anchor Chris Cuomo, who has also been critical of Trump's touting of hydroxychloroquine, was successfully treated for COVID-19 with a less safe version of the drug.
In May, multiple studies claimed that the antimalarial drug hydroxychloroquine was linked to higher rates of mortality with coronavirus patients.
"Second, the drug has not been used properly in many studies," he said.
The New York Times even alleged that Trump's motivation for touting the drug was self-serving because he holds "a small personal financial interest" in Sanofi, even though the drug is out of patent and he only owned $29 - $435 in stock as part of a mutual fund.
The VA study wasn't a clinical trial, but a small, non-peer-reviewed study of patients who were not representative of the entire population, and those with more severe COVID-19 cases were disproportionally administered the drug.
The media ignored a survey of doctors back in May that found an overwhelming majority of them "Would prescribe hydroxychloroquine or another anti-malaria drug to a family member" suffering from the coronavirus.
CNN anchor Chris Cuomo, who has also been critical of Trump's touting of hydroxychloroquine, was successfully treated for COVID-19 with a less safe version of the drug.
In May, multiple studies claimed that the antimalarial drug hydroxychloroquine was linked to higher rates of mortality with coronavirus patients.
"Second, the drug has not been used properly in many studies," he said.
No comments:
Post a Comment